Diagnostic yield of staging brain magnetic resonance imaging is low in Merkel cell carcinoma: A single-institution cohort study

Saqlain, Farees; Shalhout, Sophia Z; Emerick, Kevin S.; Kaufman, Howard L.; Chen, Yen-Lin E.; Cusack, James C.; Wright, Kayla; Miller, David M.

doi:10.1016/j.jaad.2021.08.060

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…53 The diagnostic value of magnetic resonance imaging of the neurocranium in neurologically asymptomatic patients, even with advanced disease, appears to be low, however. 54 The value of somatotropin receptor (SSTR) PET for proliferation diagnostics in MCC cannot fully be assessed as yet; in particular, any potential advantage as compared to 18F-FDG PET has not been systematically studied. [55][56][57][58] A possible additional benefit of SSTR PET may include better detection of brain metastases as well as a feasibility assessment of radionuclide therapy with SSTR-specific radiotherapeutics (theranostics).…”

Section: Diagnostic Workup At Initial Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022

Becker

Beer

DeTemple

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryMerkel cell carcinoma (MCC, ICD‐O M8247/3) is a rare, malignant, primary skin tumor with epithelial and neuroendocrine differentiation. The tumor cells share many morphologic, immunohistochemical, and ultrastructural features with cutaneous Merkel cells. Nevertheless, the cell of origin of MCC is unclear. MCC appears clinically as a reddish to purple spherical tumor with a smooth, shiny surface and a soft to turgid, elastic consistency, usually showing rapid growth. Spontaneous and often complete regressions of the tumor are observed. These likely immunologically‐mediated regressions explain the cases in which only lymph node or distant metastases are found at the time of initial diagnosis and why the tumor responds very well to immunomodulatory therapies even at advanced stages. Due to its aggressiveness, the usually given indication for sentinel lymph node biopsy, the indication of adjuvant therapies to be evaluated, as well as the complexity of the necessary diagnostics, clinical management should already be determined by an interdisciplinary tumor board at the time of initial diagnosis.

show abstract

Section: Diagnostic Workup At Initial Diagnosismentioning

confidence: 99%

“…18F‐FDG‐PET‐CT or ‐MRI offer a higher sensitivity for bone metastases 53 . The diagnostic value of magnetic resonance imaging of the neurocranium in neurologically asymptomatic patients, even with advanced disease, appears to be low, however 54 …”

Section: General Diagnostic Recommendationsmentioning

confidence: 99%

S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022

Becker

Beer

DeTemple

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Höhere Sensitivität für Knochenmetastasen bieten 18F‐FDG‐PET‐CT oder ‐MRT 53 . Der Nutzen einer Magnetresonanztomographie des Neurocraniums bei neurologisch asymptomatischen MCC‐Patienten, selbst bei fortgeschrittener Erkrankung, scheint aber gering zu sein 54 …”

Section: Diagnostikunclassified

S2k‐Leitlinie – Merkelzellkarzinom – Update 2022

Becker

Beer

DeTemple

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDas Merkelzellkarzinom (MCC, ICD‐O M8247/3) ist ein seltener, maligner, primärer Hauttumor mit epithelialer und neuroendokriner Differenzierung. Die Tumorzellen teilen viele morphologische, immunhistochemische und ultrastrukturelle Eigenschaften mit den Merkel‐Zellen der Haut. Die Ursprungszelle (cell of origin) des MCC ist dennoch unklar. Das MCC imponiert klinisch als ein rötlich bis violett farbiger kugeliger Tumor mit glatter glänzender Oberfläche und weicher bis prall‐elastischer Konsistenz, der in der Regel ein schnelles Wachstum aufweist. Spontane, häufig auch komplette Regressionen des Tumors werden beobachtet. Diese wahrscheinlich immunologisch‐vermittelten Regressionen erklären die Fälle, bei denen zum Zeitpunkt der Erstdiagnose nur Lymphknoten‐ oder Fernmetastasen gefunden werden und warum der Tumor auch in weit fortgeschrittenen Stadien sehr gut auf immunmodulierende Therapien anspricht. Aufgrund seiner Aggressivität, der in der Regel gegebenen Indikation zur Schildwächterlymphknotenbiopsie, der zu evaluierenden Indikation adjuvanter Therapien, sowie der Komplexität der notwendigen Diagnostik sollte das Vorgehen bereits bei Erstdiagnose durch ein interdisziplinäres Tumorboard festgelegt werden.

show abstract

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

Weppler¹,

Meda²,

Silva³

et al. 2023

European Journal of Cancer

View full text Add to dashboard Cite

Diagnostic yield of staging brain magnetic resonance imaging is low in Merkel cell carcinoma: A single-institution cohort study

Cited by 4 publications

References 4 publications

S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022

S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022

S2k‐Leitlinie – Merkelzellkarzinom – Update 2022

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

Contact Info

Product

Resources

About